Myofibroblast Activity in Diabetic Wound Healing: Unravelling the Diabetes Connection and Therapeutic Interventions

BDiabetic wound healing poses a significant clinical challenge due to the impaired regenerative capacity observed in individuals with diabetes. Diabetes causes a dysregulated wound healing process that is multidimensional and involves intricate interactions between cellular and molecular processes. This paper reviews discuss the activity of myofibroblasts in the context of diabetic wound healing. Myofibroblasts are specialized cells with contractile capabilities that are essential for developing scars and tissue healing. They are one of the main participants in this complex process. Wound healing is a multifaceted and ever-changing biological response involving several interrelated systems. Enzymes responsible for the control of the extracellular matrix (ECM) are tissue inhibitors of metalloproteinases (TIMPs) and matrix metalloproteinases (MMPs). The ECM is essential for wound healing, reconstruction of tissues, and other bodily processes. Diabetes and myofibroblast apoptosis have a complicated and multidimensional interaction. Diabetes is a chronic illness that needs to be managed continuously since it fails to go away on the own. This strategy has strained interest in a number of areas, including wound healing. Certain academics have looked at the possibility of repurposing medications for wound care applications, even if this could not be typical. Dipeptidyl peptidase 4, metformin, and propranolol are used in the reusing of medications for the purpose of promoting wound healing. This review provides information on the influence of diabetes on myofibroblast function and fibroblast differentiation, as well as potential treatment options associated with the affected pathways.